BRCA2-mutated breast cancers show a similar distribution across the breast cancer subtypes as sporadic tumors (approximately 70% estrogen receptor (ER)- or progesterone receptor (PR)-positive) [19], and ways to select patients with sporadic ER-positive tumors sensitive to DSB-inducing agents have been lacking thus far. This evidence concerns the gene PGR and breast cancer.